Gilead Sciences, Inc’s recently made public that its Chief Medical Officer Parsey Merdad unloaded Company’s shares for reported $15.09 million on Nov 27 ’24. In the deal valued at $91.92 per share,164,211 shares were sold. As a result of this transaction, Parsey Merdad now holds 80,801 shares worth roughly $7.6 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, ANDREW DICKINSON bought 248,645 shares, generating $23,065,258 in total proceeds.
Before that, Bluestone Jeffrey sold 6,788 shares. Gilead Sciences, Inc shares valued at $620,356 were divested by the Director at a price of $91.39 per share. As a result of the transaction, Bluestone Jeffrey now holds 8,920 shares, worth roughly $0.84 million.
Wolfe Research initiated its Gilead Sciences, Inc [GILD] rating to an Outperform in a research note published on November 15, 2024; the price target was $110. A number of analysts have revised their coverage, including Citigroup’s analysts, who began to cover the stock in mid November with a ‘”a Buy”‘ rating. Maxim Group also remained covering GILD and has decreased its forecast on November 08, 2024 with a “Hold” recommendation from previously “Buy” rating. Leerink Partners revised its rating on October 21, 2024. It rated GILD as “an Outperform” which previously was an “a Market perform”.
Price Performance Review of GILD
On Monday, Gilead Sciences, Inc [NASDAQ:GILD] saw its stock jump 1.56% to $94.02. Over the last five days, the stock has gained 4.25%. Gilead Sciences, Inc shares have risen nearly 16.06% since the year began. Nevertheless, the stocks have risen 22.74% over the past one year. While a 52-week high of $98.90 was reached on 11/11/24, a 52-week low of $62.07 was recorded on 05/31/24. SMA at 50 days reached $88.29, while 200 days put it at $75.63.
Levels Of Support And Resistance For GILD Stock
The 24-hour chart illustrates a support level at 92.89, which if violated will result in even more drops to 91.75. On the upside, there is a resistance level at 94.76. A further resistance level may holdings at 95.49. The Relative Strength Index (RSI) on the 14-day chart is 63.57, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.07, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 26.21%. Stochastics %K at 57.96% indicates the stock is a holding.
How much short interest is there in Gilead Sciences, Inc?
A steep rise in short interest was recorded in Gilead Sciences, Inc stocks on 2024-11-15, growing by 1.58 million shares to a total of 18.06 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-15 was 16.48 million shares. There was a rise of 8.73%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 17, 2024 when Bernstein began covering the stock and recommended ‘”an Outperform”‘ rating along with a $105 price target.
